Martin, Thomas
Strickland, Stephen
Glenn, Martha
Charpentier, Eric
Guillemin, Hélène
Hsu, Karl
Mikhael, Joseph
Funding for this research was provided by:
Sanofi
Baxalta
Daiichi-Sankyo
GlaxoSmithKline
Karyopharm Therapeutics
Novartis
AbbVie
Celgene
Article History
Received: 22 August 2018
Revised: 28 January 2019
Accepted: 30 January 2019
First Online: 29 March 2019
Conflict of interest
: Dr. Thomas Martin has received research funding from Sanofi. Dr. Stephen Strickland has received honoraria for an advisory role from Amgen, Alexion, Boehringer Ingelheim, Baxalta, CTI Biopharma, Sunesis, and Daiichi-Sankyo. He has also received research funding from Astellas, Boehringer Ingelheim, Celator, Celgene, Cyclacel, GlaxoSmithKline, Karyopharm Therapeutics, Novartis, Sanofi, and Sunesis. Dr. Martha Glenn declares that she has no conflict of interest. Eric Charpentier, Karl Hsu, and Hélène Guillemin are employees of Sanofi. Dr. Joseph Mikhael has received funding from Abbvie, Celgene, and Sanofi.